Sarcoma care in the era of precision medicine Article / By Wiley Knowledge Hub Sarcoma care in the era of precision medicine Read More »
Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival? Article / By Wiley Knowledge Hub Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival? Read More »
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study Article / By Wiley Knowledge Hub Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study Read More »
The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study Article / By Wiley Knowledge Hub The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study Read More »
A century of retroperitoneal soft-tissue sarcoma research: From single center experience to precision oncology? A bibliometric analysis of past, present, and future perspectives Article / By Wiley Knowledge Hub A century of retroperitoneal soft-tissue sarcoma research: From single center experience to precision oncology? A bibliometric analysis of past, present, and future perspectives Read More »
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma Article / By Wiley Knowledge Hub A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma Read More »
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy Article / By Wiley Knowledge Hub Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy Read More »
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS Article / By Wiley Knowledge Hub Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS Read More »
A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma Article / By Wiley Knowledge Hub A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma Read More »
42O A phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS) Article / By Wiley Knowledge Hub 42O A phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS) Read More »
